Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer.

ABSTRACT: Although alternative anti-androgen therapy (switching to secondary anti-androgens) is no longer recommended in the clinical guidelines of prostate cancer in light of the new hormonal and cytotoxic agents available, this therapy has proven beneficial for some patients with castration-resistant prostate cancer (CRPC). The objective of this study was to identify favorable subgroups for alternative anti-androgen therapy among CRPC patients. Eighty-eight consecutive CRPC patients treated with alternative anti-androgen therapy were included in this study. All patients were treated with bicalutamide in the initial maximum androgen blockade (MAB) and switched to flutamide in the subsequent alternative anti-androgen therapy, combined with a luteinizing hormone-releasing hormone analogue. Several cl

SUBMITTER: Suzuki K 

PROVIDER: S-EPMC6787950 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature